Pharmacokinetics and 24-Week Efficacy/Safety of Dual Boosted Saquinavir/Lopinavir/Ritonavir in Nucleoside-Pretreated Children

Abstract

Plasma drug concentrations of saquinavir, lopinavir and ritonavir were at the higher limits of expected ranges for adult treatment at approved dosages (1000/100 mg bid for saquinavir, 400/100 mg bid for lopinavir/ritonavir). The regimen was well-tolerated and had good efficacy at 24 weeks. This dual boosted protease inhibitor combination should be assessed in larger trials of reverse transcription inhibitor-experienced children.